Abstract
Aims: To determine the incidence, manifestations, and best management of sleep disturbance in Sanfilippo syndrome (mucopolysaccharidosis (MPS) type III).
Methods: Families were ascertained through the MPS societies of Australasia, the UK, and the USA. Questionnaires were sent by mail and were answered anonymously. Identical questions regarding sleep disturbance were asked about unaffected siblings to provide control data. Sleep disturbance was quantified by a total sleep disturbance score.
Results: A total of 141 responses were received; 91.5% of children with Sanfilippo syndrome had sleep disturbance and this was significantly higher than for their unaffected sibs; 77.5% of parents had used medication for this problem, with melatonin and antihistamines being most commonly used. Melatonin and benzodiazepines were reported as the most efficacious. Many different environmental modifications had been employed for this problem and some parents reported success with behavioural therapies.
Conclusions: Sleep disturbance is common, severe, and difficult to manage in Sanfilippo syndrome. Based on the parental responses and its safety profile, melatonin is the first line drug that should be tried. Behavioural therapy should be tried in all with Sanfilippo syndrome and sleep disturbance.
Full Text
The Full Text of this article is available as a PDF (61.6 KB).
Figure 1.
Frequency of responses for the age period, in years, when sleep problems began in individuals with MPS III.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bax M. C., Colville G. A. Behaviour in mucopolysaccharide disorders. Arch Dis Child. 1995 Jul;73(1):77–81. doi: 10.1136/adc.73.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cleary M. A., Wraith J. E. Management of mucopolysaccharidosis type III. Arch Dis Child. 1993 Sep;69(3):403–406. doi: 10.1136/adc.69.3.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Colville G. A., Watters J. P., Yule W., Bax M. Sleep problems in children with Sanfilippo syndrome. Dev Med Child Neurol. 1996 Jun;38(6):538–544. doi: 10.1111/j.1469-8749.1996.tb12114.x. [DOI] [PubMed] [Google Scholar]
- Fraser J., Wraith J. E., Delatycki M. B. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet. 2002 Nov;62(5):418–421. doi: 10.1034/j.1399-0004.2002.620512.x. [DOI] [PubMed] [Google Scholar]
- Jan J. E., O'Donnell M. E. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res. 1996 Nov;21(4):193–199. doi: 10.1111/j.1600-079x.1996.tb00286.x. [DOI] [PubMed] [Google Scholar]
- Leighton S. E., Papsin B., Vellodi A., Dinwiddie R., Lane R. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2001 Apr 27;58(2):127–138. doi: 10.1016/s0165-5876(01)00417-7. [DOI] [PubMed] [Google Scholar]
- Wiggs L., Stores G. Behavioural treatment for sleep problems in children with severe learning disabilities and challenging daytime behaviour: effect on daytime behaviour. J Child Psychol Psychiatry. 1999 May;40(4):627–635. [PubMed] [Google Scholar]
- Wiggs L., Stores G. Severe sleep disturbance and daytime challenging behaviour in children with severe learning disabilities. J Intellect Disabil Res. 1996 Dec;40(Pt 6):518–528. doi: 10.1046/j.1365-2788.1996.799799.x. [DOI] [PubMed] [Google Scholar]
- Wraith J. E. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis. 2001 Apr;24(2):245–250. doi: 10.1023/a:1010379320378. [DOI] [PubMed] [Google Scholar]